• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Transplant infectious disease: an official journal of the Transplantation Society >Safety and efficacy of methenamine hippurate for the prevention of recurrent urinary tract infections in adult renal transplant recipients: A single center, retrospective study
【24h】

Safety and efficacy of methenamine hippurate for the prevention of recurrent urinary tract infections in adult renal transplant recipients: A single center, retrospective study

机译：甲磺胺酸甲胺海绵预防成人肾移植受者反复性尿路感染的安全性和疗效：单一中心，回顾性研究

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Abstract Background Recurrent urinary tract infections (UTI) are an important cause of morbidity and mortality in renal transplant recipients (RTR). Methods In this retrospective study we gathered clinical data from patients prescribed methenamine hippurate to prevent recurrent UTI pre‐ and post‐intervention. Thirty‐eight RTR ≥18?years old at Northwestern Memorial Hospital from 2006‐2017 were included in the final analysis. Results The median and range for follow‐up days were 365 (299‐365) pre‐ vs 314 (105‐365) post‐methenamine. Total UTI frequency (9.16 vs 5.01/1000 patient follow‐up days), days of antibiotic therapy to treat UTI (215 vs 132/1000 patient follow‐up days), and hospitalization due to UTI (2.64 vs 1.07/1000 patient follow‐up days) decreased while patients took methenamine. Escherichia coli and Klebsiella pneumoniae were the most commonly identified cause of UTI both pre‐ and post‐intervention. Drug resistant bacteria (ESBL‐producing or VRE) affected 3 patients pre‐ and recurred in 1 of those patients plus 3 new patients post‐methenamine. Methenamine had few adverse side effects for patients. One patient had nausea and 1 was intolerant. Conclusion We found that methenamine is well tolerated and is useful in reducing UTI, antibiotic prescriptions, and hospitalization in RTR with recurrent UTI. Larger prospective studies are needed to confirm these findings.
机译：摘要背景经常发生的尿路感染（UTI）是肾移植受者（RTR）中发病率和死亡率的重要原因。该回顾性研究中的方法我们收集了来自规定的甲磺胺酸甲胺的患者临床数据，以防止复发性UTI预先和干预后。 2006 - 2017年从西北纪念医院历史上三十八岁历史，归纳于最终分析。结果后续天中的中位数和范围是314（105-365）后甲磺胺胺。 uti频率（9.16 vs 5.01 / 1000患者随访日），治疗UTI的天数（215 vs 132/1000患者随访日），并因UTI而住院（2.64 Vs 1.07 / 1000患者患者服用甲磺胺时，上天减少。大肠杆菌和Klebsiella肺炎是最常见的UTI既有介入和干预后的最常见原因。耐药细菌（ESBL-生产或VRE）影响了3名患者的3例，并重来的患者加上3名甲胺酮的新患者。甲胺酮对患者的不良副作用很少。一名患者有恶心，1次较不耐受。结论我们发现甲磺胺是良好的耐受性，可用于减少uti，抗生素处方和在RTR中的住院治疗反复性UTI。需要更大的前瞻性研究来确认这些发现。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号